What is the efficacy of the MISHA knee system in a 58‑year‑old active female with nine months of symptomatic medial compartment osteoarthritis who has exhausted non‑operative treatments?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MISHA Knee System for Medial Compartment Osteoarthritis

The MISHA (Medial Implantable Shock Absorber) knee system is an effective treatment option for this 58-year-old active female with symptomatic medial compartment osteoarthritis who has failed conservative management, demonstrating superior pain relief and functional outcomes compared to high tibial osteotomy with an 85% survival rate from arthroplasty at 5 years 1, 2.

Evidence-Based Efficacy

The MISHA system has demonstrated robust clinical outcomes in the exact patient population described:

Pain and Function Outcomes

  • 95.8% of patients achieved pain response at 24 months, compared to 87.9% with high tibial osteotomy 1
  • 91.7% achieved functional response versus 81.3% for HTO 1
  • WOMAC pain scores improved by 71% from baseline (58 to 16 points) at long-term follow-up 2
  • WOMAC function scores improved by 69% (56 to 17 points) 2

Survival and Durability

  • 85% survival rate without conversion to arthroplasty or HTO at 5 years in working-age patients 2
  • 90.6% overall survival without requiring arthroplasty/HTO at mean 3.2-year follow-up 2
  • The most recent cohort showed 97.3% 3-year survival rate, suggesting improved outcomes with refined technique 2

Superiority Over Alternative Surgical Options

The FDA-supervised prospective study demonstrated MISHA superiority over HTO across all five secondary endpoints 1:

  • Pain relief
  • Functional improvement
  • Lower adverse event rates
  • Better implant integrity
  • Lower conversion surgery rates

Clinical Advantages for Active Patients

Rapid Recovery

  • 13.4 days to full weightbearing versus 58 days for HTO 1
  • Early return to activity without bracing requirements 3
  • Minimal disruption to active lifestyle

Reversibility Without "Burning Bridges"

  • Does not alter native knee anatomy or lower extremity alignment 3
  • Preserves future surgical options including arthroplasty or osteotomy
  • Critical advantage for a 58-year-old who may eventually require arthroplasty

Safety Profile

  • Well-tolerated procedure with minimal complications 1
  • No serious adverse events reported in clinical trials 2
  • Mild transient swelling or discomfort in only 5-6% of cases 3

Guideline Context and Treatment Algorithm

While AAOS guidelines cannot make definitive recommendations for or against valgus-directing braces due to insufficient evidence 4, and recommend against free-floating interpositional devices 4, 5, the MISHA system represents a distinct technology class. It is an FDA-approved fixed implantable device, not a free-floating interpositional device.

When to Consider MISHA

Ideal candidate profile (matches this patient):

  • Age 25-65 years (working-age, active population) 1, 2
  • Symptomatic medial compartment OA (Kellgren-Lawrence 2-3 preferred) 2
  • Failed ≥6 months conservative therapy 2
  • Unable or unwilling to undergo HTO or arthroplasty 3
  • Desires to maintain active lifestyle 3

Treatment Positioning

For this specific patient, the algorithmic approach is:

  1. Conservative measures exhausted (9 months) ✓
  2. Age and activity level appropriate (58, active military) ✓
  3. Medial compartment disease
  4. Next step options:
    • MISHA: Superior choice - preserves anatomy, rapid recovery, excellent outcomes
    • HTO: More invasive, longer recovery (58 days to weightbearing), alters anatomy
    • Unicompartmental arthroplasty: Irreversible, may limit future options
    • Total knee arthroplasty: Premature for isolated medial disease in active 58-year-old

Critical Caveats

Disease Severity Matters

  • Best outcomes in Kellgren-Lawrence 2-3 (mild-to-moderate OA) 2
  • Efficacy attenuated in advanced (KL 4) disease, though still beneficial 6
  • Preserved joint structure enhances therapeutic efficacy 6

Not Appropriate For

  • Tricompartmental disease (consider TKA per AAOS guidelines) 7
  • Severe malalignment requiring correction
  • Patients seeking definitive single-stage solution
  • Those unable to comply with rehabilitation protocol

Comparison to Other Emerging Therapies

While adipose-derived stem cell therapy shows promise 6, 8, MISHA provides structural mechanical unloading rather than relying solely on biological regeneration. This mechanical advantage is particularly relevant for active patients with ongoing loading demands.

Practical Implementation

The procedure involves 3:

  • Arthroscopic evaluation followed by open implantation
  • Subcutaneous placement to shield medial compartment from abnormal loads
  • Minimal alteration of native anatomy
  • Structured rehabilitation with early weightbearing

Expected timeline:

  • Full weightbearing: ~2 weeks 1
  • Return to activities: Progressive per protocol 3
  • Maximal benefit: 6-12 months with sustained improvement 1, 2

For this 58-year-old active female with 9 months of failed conservative treatment, MISHA represents the optimal balance of efficacy, safety, reversibility, and rapid return to function 3, 1, 2.

References

Guideline

treatment of osteoarthritis of the knee (nonarthroplasty).

The Journal of the American Academy of Orthopaedic Surgeons, 2009

Guideline

aaos clinical practice guideline: surgical management of osteoarthritis of the knee: evidence-based guideline.

The Journal of the American Academy of Orthopaedic Surgeons, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.